- Home
- SGMT
as 11-14-2024 4:00pm EST
Stocks
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | SAN MATEO |
| Market Cap: | 93.7M | IPO Year: | 2023 |
| Target Price: | $21.60 | AVG Volume (30 days): | 772.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.14 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.25 - $20.71 | Next Earning Date: | 11-13-2024 |
| Revenue: | $2,000,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Sagimet Biosciences Inc. Series A News
SGMT Breaking Stock News: Dive into SGMT Ticker-Specific Updates for Smart Investing
GlobeNewswire
20 hours ago
Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
GlobeNewswire
8 days ago
Sagimet Biosciences to Participate in the UBS Global Healthcare Conference
GlobeNewswire
17 days ago
Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024
GlobeNewswire
a month ago
Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024
GlobeNewswire
a month ago
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
GlobeNewswire
a month ago
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH
GlobeNewswire
a month ago
Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2 months ago
Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit
Compare SGMT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SGMT Sagimet Biosciences Inc. Series A - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.